MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
Acasti Pharma Operating Income 2011-2026 | ACST
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Acasti Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -16.7 M | -12.9 M | -52.2 M | -15.6 M | -16.4 M | -24.4 M | -34.4 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.9 M | -52.2 M | -24.6 M |
Quarterly Operating Income Acasti Pharma
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.45 M | -2.53 M | -3.09 M | - | -3.7 M | -4.83 M | -4.96 M | - | -3.04 M | -2.09 M | -4.45 M | - | -4.24 M | -5.11 M | -4.73 M | - | -4.47 M | -11.2 M | -6.71 M | - | -1.96 M | -1.96 M | -8.03 M | -4.12 M | -6.15 M | -6.26 M | -8.01 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.96 M | -11.2 M | -4.73 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-156 M | $ 2.19 | -9.77 % | $ 226 M |  USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Cabaletta Bio
CABA
|
-74.7 M | $ 3.34 | 0.45 % | $ 3.9 M | USA |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Codexis
CDXS
|
-58.5 M | $ 1.02 | 1.49 % | $ 74.9 M | USA |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 3.74 | 3.6 % | $ 1.12 B |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Cerus Corporation
CERS
|
-14.2 M | $ 2.6 | 1.37 % | $ 480 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cellectis S.A.
CLLS
|
-131 M | $ 3.87 | -0.39 % | $ 116 M | France |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
CNS Pharmaceuticals
CNSP
|
-14.9 M | $ 3.23 | 2.22 % | $ 1.23 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Collegium Pharmaceutical
COLL
|
60.8 M | $ 41.75 | 0.19 % | $ 1.32 B | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
44.8 M | $ 36.14 | 1.23 % | $ 3.75 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Amarin Corporation plc
AMRN
|
-67.6 M | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
Aileron Therapeutics
ALRN
|
-65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
258 M | $ 23.77 | 2.99 % | $ 2.91 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-45.1 M | $ 8.41 | -1.87 % | $ 36.4 M | USA |
 |
Cardiff Oncology
CRDF
|
-49 M | $ 1.94 | 0.01 % | $ 130 M | USA |
 |
Curis
CRIS
|
-44.5 M | $ 1.1 | -3.51 % | $ 6.94 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
CorMedix
CRMD
|
-49 M | $ 7.16 | 0.42 % | $ 364 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
|
Champions Oncology
CSBR
|
4.55 M | $ 6.14 | 3.89 % | $ 83.9 M | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-42 M | $ 0.72 | -2.34 % | $ 4.84 M | USA |
 |
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-30 M | - | 17.91 % | $ 11.1 M | USA |
 |
Altimmune
ALT
|
-103 M | $ 4.21 | -2.32 % | $ 299 M | USA |
 |
CEL-SCI Corporation
CVM
|
-26.4 M | $ 3.88 | -8.92 % | $ 247 M | USA |